Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 1, 2026, 4:39 PM EST

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 913–936 of 5,231 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Infection Clear all
Not yet recruiting Not applicable Interventional

Hyperbaric Oxygen Treatment for Necrotizing Fasciitis and Necrotizing Soft Tissue Infections

NCT07170020
View directory record Official record
Conditions
Necrotizing Fascitis
Interventions
Hyperbaric Oxygen Therapy
Procedure
Lead sponsor
Corewell Health West
Other
Eligibility
18 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Grand Rapids, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 12, 2025 · Synced Nov 1, 2026, 4:39 PM EST
Terminated Phase 1 Interventional Accepts healthy volunteers

Safety, Tolerability and Pharmacokinetic First in Human (FIH) Study for Intravenous (IV) TKM-100802

NCT02041715
View directory record Official record
Conditions
Ebola Virus Infection
Interventions
TKM-100802 for Injection, Placebo
Drug
Lead sponsor
Arbutus Biopharma Corporation
Industry
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Aug 7, 2015 · Synced Nov 1, 2026, 4:39 PM EST
Completed No phase listed Observational

Prospective Comparison of the Tuberculin Skin Test and Interferon-Gamma Release Assays in Diagnosing Infection With Mycobacterium Tuberculosis and in Predicting Progression to Tuberculosis

NCT01622140
View directory record Official record
Conditions
Latent Tuberculosis Infection, Tuberculosis
Interventions
Not listed
Lead sponsor
Centers for Disease Control and Prevention
Federal
Eligibility
Not listed
Enrollment
21,334 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
10
States / cities
Phoenix, Arizona • Richmond, California • Denver, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 28, 2021 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 1 Interventional

A Randomized Study of Activity, Safety, and Tolerance of Oral Ro 24-7429 (Tat Antagonist) in Patients With HIV Infection

NCT00000760
View directory record Official record
Conditions
HIV Infections
Interventions
Ro 24-7429, Zidovudine, Didanosine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
4
States / cities
San Diego, California • Baltimore, Maryland • Boston, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 4, 2008 · Synced Nov 1, 2026, 4:39 PM EST
Not listed Phase 2 Interventional

Safety and Efficacy of ADAPTAVIR's Ability to Eliminate Treatment-Resistant Infectious Virus in Peripheral Blood Mononuclear Cells (PBMCs)

NCT00951743
View directory record Official record
Conditions
HIV Infections
Interventions
Adaptavir (monomeric DAPTA)
Drug
Lead sponsor
Rapid Laboratories Inc.
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Aug 11, 2009 · Synced Nov 1, 2026, 4:39 PM EST
Terminated Phase 2 Interventional

The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors

NCT00002418
View directory record Official record
Conditions
HIV Infections
Interventions
Emivirine, Hydroxyurea, Nevirapine, Stavudine, Didanosine
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
5
States / cities
Beverly Hills, California • Denver, Colorado • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 14, 2008 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 1 Interventional

Adjuvant Cytokine Therapy to Treat Pulmonary Mycobacterium Avium Complex Infection

NCT00111397
View directory record Official record
Conditions
Mycobacterium Avium-Intracellulare Infection
Interventions
Cytokine therapy, Interferon Gamma, GM-CSF
Procedure · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older · Female only
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Nov 1, 2026, 4:39 PM EST
Completed Not applicable Interventional

Laser Hair Removal for Treatment of Pilonidal Disease

NCT03949140
View directory record Official record
Conditions
Pilonidal Disease
Interventions
Laser hair removal
Procedure
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
13 Years to 35 Years
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 17, 2021 · Synced Nov 1, 2026, 4:39 PM EST
Active, not recruiting Phase 2 Interventional

Autologous Fecal Microbiota Transplantation (Auto-FMT) for Prophylaxis of Clostridium Difficile Infection in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation

NCT02269150
View directory record Official record
Conditions
Allogeneic Hematopoietic Stem Cell
Interventions
fecal microbiota transplantation (FMT), No fecal microbiota transplantation (FMT), routine management
Biological · Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
59 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 17, 2025 · Synced Nov 1, 2026, 4:39 PM EST
Completed No phase listed Observational

Multinational Study of Acinetobacter Bloodstream Infection: Clinical Outcomes and Global Epidemiology-PITT Protocol

NCT00524290
View directory record Official record
Conditions
Acinetobacter Infections
Interventions
Not listed
Lead sponsor
University of Pittsburgh
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2017
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 14, 2018 · Synced Nov 1, 2026, 4:39 PM EST
Completed Not applicable Interventional Accepts healthy volunteers

Multimedia WORTH With Black Drug-Involved Women on Probation

NCT02391233
View directory record Official record
Conditions
Sexually Transmitted Infections, HIV, Gonorrhea, Trichomonas, Chlamydia Trachomatis, Drug Use
Interventions
E-WORTH, Streamlined HIV Testing
Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Female only
Enrollment
354 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 27, 2020 · Synced Nov 1, 2026, 4:39 PM EST
Recruiting Phase 3 Interventional Accepts healthy volunteers

Azithromycin Prophylaxis for PRElabor CEsarean DElivery Trial

NCT06605118
View directory record Official record
Conditions
Obstetrical Complications, Labor and Delivery Complication, Cesarean Delivery
Interventions
Azithromycin Injection, Placebo, Standard of Care Preoperative antibiotics
Drug
Lead sponsor
The George Washington University Biostatistics Center
Other
Eligibility
Female only
Enrollment
8,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Chicago, Illinois + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 9, 2026 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 2 Interventional

A Study of Hepatitis C Virus (HCV) Polymerase Inhibitor Pro-Drug in Combination With PEGASYS With or Without COPEGUS in Patients With Chronic Hepatitis C (CHC) Genotype 1 Infection.

NCT00377182
View directory record Official record
Conditions
Hepatitis C, Chronic
Interventions
Copegus, PEGASYS, RO5024048 1500mg, RO5024048 3000mg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 65 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
17
States / cities
La Jolla, California • Long Beach, California • Sacramento, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 1Phase 2 Interventional

Sildenafil for PNTM Infection

NCT01853540
View directory record Official record
Conditions
Nontuberculous Mycobacterial Infection
Interventions
Sildenafil
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 25, 2015 · Synced Nov 1, 2026, 4:39 PM EST
Completed Not applicable Interventional Results available

Establishing Novel Antiretroviral Imaging for Hair to Elucidate Non-Adherence (ENLIGHTEN)

NCT04232540
View directory record Official record
Conditions
Medication Adherence
Interventions
MedViewer report
Device
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years to 99 Years
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 12, 2022 · Synced Nov 1, 2026, 4:39 PM EST
Terminated Phase 4 Interventional Results available

HIV Viremia and Persistence in Acutely HIV-Infected Patients Treated With Darunavir/Ritonavir and Etravirine

NCT00855413
View directory record Official record
Conditions
Acute HIV Infection, HIV Infections
Interventions
Darunavir, Ritonavir, Etravirine
Drug
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Chapel Hill, North Carolina • Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 17, 2017 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 2 Interventional Results available

Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma

NCT01092182
View directory record Official record
Conditions
Burkitt Lymphoma, Diffuse Large B-cell Lymphoma, c-MYC Positive, Plasmablastic Lymphoma
Interventions
EPOCH-R, EPOCH-RR
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
194 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2023
U.S. locations
30
States / cities
La Jolla, California • Los Angeles, California • Atlanta, Georgia + 22 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Nov 1, 2026, 4:39 PM EST
Completed Not applicable Interventional Results available

Checklist to Prevent MRSA Surgical Site Infections

NCT02216227
View directory record Official record
Conditions
Surgical Site Infection
Interventions
Mupirocin, Chlorhexidine gluconate, Cefazolin, Vancomycin, Nasal Povidone Iodine
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
23,005 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
11
States / cities
Miami, Florida • Iowa City, Iowa • Baltimore, Maryland + 8 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 2 Interventional

A Phase II/III Trial of Rifampin, Ciprofloxacin, Clofazimine, Ethambutol, and Amikacin in the Treatment of Disseminated Mycobacterium Avium Infection in HIV-Infected Individuals.

NCT00000641
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Ciprofloxacin hydrochloride, Ethambutol hydrochloride, Amikacin sulfate, Azithromycin, Rifampin, Clofazimine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1994
U.S. locations
16
States / cities
Torrance, California • Indianapolis, Indiana • St Louis, Missouri + 10 more
Source: ClinicalTrials.gov public record
Updated Nov 3, 2021 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 2 Interventional

Interleukin-2 Therapy for HIV Infection - Supplemental Procedures

NCT00001354
View directory record Official record
Conditions
Acquired Immunodeficiency Syndrome, HIV Infection
Interventions
Interleukin-2/Zidovudine (AZT)
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
Not listed
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Nov 1, 2026, 4:39 PM EST
Active, not recruiting Phase 4 Interventional Accepts healthy volunteers

Adherence to Vaginal Estrogen Therapy in Hypoestrogenic Women With Recurrent Urinary Tract Infections

NCT06353269
View directory record Official record
Conditions
Recurrent Urinary Tract Infection, Hypoestrogenism
Interventions
Estring Vaginal Product, Vagifem, Estrace 0.01% Vaginal Cream
Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
111 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Study of Inactivated, Split-Virion Influenza Vaccine and Standard Fluzone® Vaccine in Adult and Elderly Subjects

NCT00551031
View directory record Official record
Conditions
Influenza, Myxovirus Infection
Interventions
Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 1), Split, Inactivated, Trivalent Influenza Vaccine (Intradermal Formulation 2), Split, Inactivated, Trivalent Influenza Vaccine (Standard dose), Split, Inactivated, Trivalent Influenza Vaccine (High-dose)
Biological
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
2,098 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
29
States / cities
Alabaster, Alabama • Mobile, Alabama • Chandler, Arizona + 26 more
Source: ClinicalTrials.gov public record
Updated May 16, 2016 · Synced Nov 1, 2026, 4:39 PM EST
Completed Phase 1Phase 2 Interventional

A Double-Blind, Active-Controlled, Multiple-Ascending Dose Study of Aerosolized RSP-1502 in Subjects With CF and Chronic PA Lung Infection

NCT06016088
View directory record Official record
Conditions
Cystic Fibrosis Lung, Respiratory Infections, Recurrent, Chronic, Pseudomonas Aeruginosa
Interventions
RSP-1502, Tobramycin inhalation solution
Drug
Lead sponsor
Respirion Pharmaceuticals Pty Ltd
Industry
Eligibility
12 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
13
States / cities
Tucson, Arizona • Los Angeles, California • Palo Alto, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2026 · Synced Nov 1, 2026, 4:39 PM EST
Completed No phase listed Observational

Association Between Hepatitis C Infection and Renal Cell Carcinoma

NCT01405183
View directory record Official record
Conditions
Hepatitis C, Renal Cell Carcinoma, Colorectal Cancer
Interventions
Hepatitis C testing
Other
Lead sponsor
Henry Ford Health System
Other
Eligibility
18 Years and older
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Sep 17, 2014 · Synced Nov 1, 2026, 4:39 PM EST